TG Therapeutics (TGTX) Misses Q2 EPS by 10c

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.34), $0.10 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $16.3 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• Morgan Stanley sees quality stocks and AI adopters leading market
• MetLife (MET) PT Raised to $106 at Evercore ISI